$ACET
Adicet Bio Inc
PRICE
$5.26 -
Extented Hours
VOLUME
249,744
DAY RANGE
5.24 - 5.48
52 WEEK
4.61 - 21.87
Key Metrics
Market Cap
229.82 M
Beta
1.15
Avg. Volume
352.44 K
Shares Outstanding
42.96 M
Yield
0%
Public Float
0
Next Earnings Date
2023-08-10
Next Dividend Date
Company Information
adicet bio, inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. adicet is developing novel universal immune cell therapies based on gamma delta t cells engineered with chimeric antigen receptors (cars) or t cell receptors (tcrs). adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating tcr-like mabs (tcrls) directed to these cancer-specific peptide targets presented by mhc class i complexes. these tcrls can be used to arm t cells, as t cell engagers or as antibody drug conjugates (adc). in august 2016, adicet entered a strategic collaboration with regeneron pharmaceuticals, inc. to develop next-generation engineered immune-cell therapeutics using adicetβs gamma delta t cell allogeneic platform technology. adicet bio raised $51m in series a financing led by orbimed partners, orbimed israel, novartis v
CEO: Chen Schor
Website: adicetbio.com
HQ: 500 Boylston St Fl 12 Boston, 02116-3740 Massachusetts
Related News